203 related articles for article (PubMed ID: 28229357)
1. Experimental Determination and Theoretical Calculation of the Eutectic Composition of Cefuroxime Axetil Diastereomers.
Dalal N; Buckner IS; Wildfong PLD
AAPS PharmSciTech; 2017 Oct; 18(7):2570-2578. PubMed ID: 28229357
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of stability of cefuroxime axetil in solid state.
Zajac M; Jelińska A; Dobrowolski L; Oszczapowicz I
J Pharm Biomed Anal; 2003 Aug; 32(6):1181-7. PubMed ID: 12907262
[TBL] [Abstract][Full Text] [Related]
3. The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.
Nguyen NA
Pharm Res; 1991 Jul; 8(7):893-8. PubMed ID: 1924141
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective absorption and hydrolysis of cefuroxime axetil diastereomers using the Caco-2 cell monolayer model.
Barrett MA; Lawrence MJ; Hutt AJ; Lansley AB
Eur J Drug Metab Pharmacokinet; 1997; 22(4):409-13. PubMed ID: 9512942
[TBL] [Abstract][Full Text] [Related]
5. Photoisomerization kinetics of cefuroxime axetil and related compounds.
Fabre H; Ibork H; Lerner DA
J Pharm Sci; 1994 Apr; 83(4):553-8. PubMed ID: 8046613
[TBL] [Abstract][Full Text] [Related]
6. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids.
Jun SW; Kim MS; Jo GH; Lee S; Woo JS; Park JS; Hwang SJ
J Pharm Pharmacol; 2005 Dec; 57(12):1529-37. PubMed ID: 16354397
[TBL] [Abstract][Full Text] [Related]
7. STUDIES OF THE CRYSTALLINE FORM OF CEFUROXIME AXETIL: IMPLICATIONS FOR ITS COMPATIBILITY WITH EXCIPIENTS.
Talaczynska A; Mizera M; Szybowicz M; Nowicka AB; Garbacki P; Paczkowska M; Zalewski P; Kozak M; Oszczapowicz I; Jelinska A; Cielecka-Piontek J
Acta Pol Pharm; 2016 Sep; 73(5):1299-1309. PubMed ID: 29638070
[TBL] [Abstract][Full Text] [Related]
8. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants.
Zhang JY; Shen ZG; Zhong J; Hu TT; Chen JF; Ma ZQ; Yun J
Int J Pharm; 2006 Oct; 323(1-2):153-60. PubMed ID: 16828244
[TBL] [Abstract][Full Text] [Related]
9. Enantiomeric 3-chloromandelic acid system: binary melting point phase diagram, ternary solubility phase diagrams and polymorphism.
Le Minh T; von Langermann J; Lorenz H; Seidel-Morgenstern A
J Pharm Sci; 2010 Sep; 99(9):4084-95. PubMed ID: 20575001
[TBL] [Abstract][Full Text] [Related]
10. The stability of the amorphous form of cefuroxime axetil in solid state.
Jelińska A; Dudzińska I; Zajac M; Oszczpowicz I
J Pharm Biomed Anal; 2006 Jun; 41(3):1075-81. PubMed ID: 16563687
[TBL] [Abstract][Full Text] [Related]
11. Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.
Law D; Wang W; Schmitt EA; Long MA
Pharm Res; 2002 Mar; 19(3):315-21. PubMed ID: 11934239
[TBL] [Abstract][Full Text] [Related]
12. [Crystalline polymorphism of eflucimibe].
Ribet JP; Pena R; Chauvet A; Patoiseau JF; Autin JM; Segonds R; Basquin M; Autret JM
Ann Pharm Fr; 2002 May; 60(3):177-86. PubMed ID: 12050596
[TBL] [Abstract][Full Text] [Related]
13. Liquid antisolvent preparation of amorphous cefuroxime axetil nanoparticles in a tube-in-tube microchannel reactor.
Zhu WZ; Wang JX; Shao L; Zhang HX; Zhang QX; Chen JF
Int J Pharm; 2010 Aug; 395(1-2):260-5. PubMed ID: 20493936
[TBL] [Abstract][Full Text] [Related]
14. Thermal behavior of a pharmaceutical solid acetaminophen doped with p-aminophenol.
Faroongsarng D; Kadejinda W; Sunthornpit A
AAPS PharmSciTech; 2000 Jul; 1(3):E23. PubMed ID: 14727909
[TBL] [Abstract][Full Text] [Related]
15. Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability.
Dhumal RS; Biradar SV; Aher S; Paradkar AR
J Pharm Pharmacol; 2009 Jun; 61(6):743-51. PubMed ID: 19505364
[TBL] [Abstract][Full Text] [Related]
16. Differentiating amorphous mixtures of cefuroxime axetil and copovidone by X-ray diffraction and differential scanning calorimetry.
Nicolaï B; Perrin MA; Céolin R; Rietveld IB
Ann Pharm Fr; 2014 Mar; 72(2):95-100. PubMed ID: 24630310
[TBL] [Abstract][Full Text] [Related]
17. Application of vibrational spectroscopy supported by theoretical calculations in identification of amorphous and crystalline forms of cefuroxime axetil.
Talaczyńska A; Lewandowska K; Jelińska A; Garbacki P; Podborska A; Zalewski P; Oszczapowicz I; Sikora A; Kozak M; Cielecka-Piontek J
ScientificWorldJournal; 2015; 2015():921049. PubMed ID: 25654137
[TBL] [Abstract][Full Text] [Related]
18. Crystallization of D-mannitol in binary mixtures with NaCl: phase diagram and polymorphism.
Telang C; Suryanarayanan R; Yu L
Pharm Res; 2003 Dec; 20(12):1939-45. PubMed ID: 14725357
[TBL] [Abstract][Full Text] [Related]
19. An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. III. The use of DSC and HSDSC as means of characterising the interaction of the microspheres with buffered media.
Robson H; Craig DQ; Deutsch D
Int J Pharm; 2000 May; 201(2):211-9. PubMed ID: 10878327
[TBL] [Abstract][Full Text] [Related]
20. Preparation of amorphous cefuroxime axetil nanoparticles by sonoprecipitation for enhancement of bioavailability.
Dhumal RS; Biradar SV; Yamamura S; Paradkar AR; York P
Eur J Pharm Biopharm; 2008 Sep; 70(1):109-15. PubMed ID: 18502628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
